.
New Delhi, April 26 (MondayMirror.com) The Drugs Controller General of India (DCGI) on Tuesday approved the restricted emergency use authorisation (EUA) to Bharat Biotech’s Covaxin for children between the age of 6-12 years, sources said.
The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.
This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.
However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.
Source: IANS
The 369 manifestation method has become one of the most talked about techniques in 2026,…
Gulab Chand Kataria, Administrator of Chandigarh, made a significant announcement regarding key civic issues, stating…
The TiECON Chandigarh 2026 brings back its special showcase of emerging startups that are redefining…
Underlining that more than 50% Startups today are being registered in Tier 2 and Tier…
Narrating their real life stories of unfiltered passion, courage and determination, 3 super achievers including…
Haryana Chief Minister, Nayab Singh Saini said that the government has implemented several new initiatives…